NIAID Site Search

A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. The trial aims to understand if different vaccine regimens—prototype and variant vaccines alone and in combinations—can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Published: March 31, 2022

A NIAID-supported Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic COVID-19 in adults has begun.

Published: July 27, 2020

Jordan Report: Accelerated Development of Vaccines (2007) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: August 6, 2019

Jordan Report: Accelerated Development of Vaccines (2002) from NIAID includes updates on vaccine research for specific infectious diseases.

Last Reviewed: December 31, 2002

NIH Opening Statement Senate LHHS FY 2019 Hearing: Prepared statement of Lawrence A. Tabak, D.D.S., PH.D., Principal Deputy Director, Office of the Director

Last Reviewed: August 16, 2018

A NIAID-supported Phase 3 clinical trial evaluating an investigational COVID-19 vaccine called AZD1222 will enroll around 30,000 adult volunteers.

Published: August 31, 2020

A fourth Phase 3 NIH clinical trial evaluating an investigational vaccine for coronavirus disease 2019 (COVID-19) has begun enrolling adult volunteers.

Published: September 23, 2020